Himalaya Nutravedics IPO
Himalaya Nutravedics IPO is a BSE SME book-built issue of ₹26.50 crore, consisting entirely of a Fresh Issue of 25.00 lakh equity shares with no Offer for Sale. The price band is ₹100 to ₹106 per share, with a lot size of 1,200 shares. The IPO opens on Se
Himalaya Nutravedics IPO Details
Himalaya Nutravedics IPO bidding starts from September 22, 2026 and ends on September 24, 2026. The allotment for Himalaya Nutravedics IPO is expected to be finalized on September 25, 2026. Himalaya Nutravedics IPO is proposed to list on BSE SME on September 29, 2026.
Himalaya Nutravedics IPO Timeline (Tentative)
Himalaya Nutravedics IPO is scheduled to open for subscription on September 22, 2026 and close on September 24, 2026. The basis of allotment is expected to be finalized on September 25, refunds are scheduled to begin on September 28, and shares are expected to be credited to successful applicants' Demat accounts on the same day. The shares are proposed to be listed on BSE SME on September 29, 2026.
| Event | Tentative Date |
|---|---|
| IPO Open Date | Tue, Sep 22, 2026 |
| IPO Close Date | Thu, Sep 24, 2026 |
| Basis of Allotment | Fri, Sep 25, 2026 |
| Initiation of Refunds | Mon, Sep 28, 2026 |
| Credit of Shares to Demat | Mon, Sep 28, 2026 |
| Listing Date | Tue, Sep 29, 2026 |
| IPO Opens | September 22, 2026 |
| IPO Closes | September 24, 2026 |
| Basis of Allotment | September 25, 2026 |
| Refund Initiation | September 28, 2026 |
| Credit of Shares to Demat | September 28, 2026 |
| Listing Date | September 29, 2026 |
Himalaya Nutravedics IPO Lot Size
The Himalaya Nutravedics IPO lot size is 1,200 shares. At the upper price band of ₹106 per share, one lot represents an investment of ₹1,27,200. Retail investors are required to apply for a minimum of 2 lots, or 2,400 shares, amounting to ₹2,54,400 at the upper price band.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,400 | ₹2,54,400 |
| Retail (Max) | 2 | 2,400 | ₹2,54,400 |
| S-HNI (Min) | 3 | 3,600 | ₹3,81,600 |
| S-HNI (Max) | 7 | 8,400 | ₹8,90,400 |
| B-HNI (Min) | 8 | 9,600 | ₹10,17,600 |
Himalaya Nutravedics IPO Reservation
Himalaya Nutravedics IPO comprises a total issue size of 25,00,000 shares. The entire issue is a fresh issue. As per the issue structure, not more than 50% of the net offer is reserved for QIBs, not less than 15% for NIIs and not less than 35% for retail individual investors.
Himalaya Nutravedics IPO Subscription
Himalaya Nutravedics IPO is an upcoming issue as of September 16, 2026. Final subscription figures are not yet available because bidding is scheduled to begin on September 22, 2026.
| Category | Subscription (times) |
|---|---|
| QIB | N.A. |
| NII | N.A. |
| RII | N.A. |
| Total | N.A. |
About Himalaya Nutravedics
Himalaya Nutravedics India Limited, incorporated in June 2022, is a Hyderabad-based Ayurvedic and nutraceutical manufacturing company engaged in the formulation, manufacturing and marketing of Ayurvedic and nutraceutical products. Its product portfolio includes Softgel Capsules, Tablets, Medicated Oils, Liquid Orals, Hardgel Capsules and Protein Powders across therapeutic categories such as digestive health, immunity, metabolic health and pain management.
The company markets its branded products through healthcare practitioners and also undertakes third-party contract manufacturing. Its business has expanded across multiple Indian states and its manufacturing facility is located in Hyderabad, Telangana.
The company’s official website describes its business as combining Ayurvedic knowledge with modern nutraceutical formulation and manufacturing capabilities. Its services include contract manufacturing, loan licensing and own-brand marketing. The company also states that its manufacturing and quality systems follow applicable FSSAI, AYUSH, GMP and ISO-related standards.
Strengths
- sing and own-brand marketing. The company also states that its manufacturing and quality systems follow applicable FSSAI, AYUSH, GMP and ISO-related standards.
- Strengths :
- Integrated manufacturing capabilities across multiple dosage forms including softgels, tablets, liquid orals, medicated oils, capsules and powders.
- Presence across Ayurvedic and nutraceutical product categories covering areas such as digestive health, immunity, metabolic health and pain management.
- Doctor and healthcare-practitioner-oriented marketing approach for branded products.
- Third-party contract manufacturing capability alongside its own branded product portfolio.
- Geographic expansion across multiple states in India.
- Manufacturing and quality systems supported by certifications and regulatory compliance frameworks.
Risks to Consider
- The supplied IPO information does not provide a separate detailed Risks field.
- Investors should review the Risk Factors section of the DRHP/RHP for company-specific risks, including risks relating to the company's operating history, competition, manufacturing operations, customer and supplier relationships, regulatory requirements and the proposed use of IPO proceeds.
Himalaya Nutravedics Financials (₹ Cr)
Himalaya Nutravedics reported strong growth in total income and profit over the last three financial years. Total income increased from ₹14.43 crore in FY2024 to ₹21.00 crore in FY2025 and ₹43.12 crore in FY2026. Profit after tax increased from ₹0.43 crore in FY2024 to ₹2.23 crore in FY2025 and ₹7.39 crore in FY2026. EBITDA also increased from ₹0.94 crore in FY2024 to ₹2.99 crore in FY2025 and ₹8.10 crore in FY2026.
| Period | Revenue | PAT | Total Assets | Net Worth |
|---|---|---|---|---|
| FY2026 | ₹43.12 Cr | ₹7.39 Cr | ₹24.42 Cr | ₹16.38 Cr |
| FY2025 | ₹21.00 Cr | ₹2.23 Cr | ₹10.82 Cr | ₹6.75 Cr |
| FY2024 | ₹14.43 Cr | ₹0.43 Cr | ₹6.09 Cr | ₹1.34 Cr |
KPIs & Valuation
At the IPO price band of ₹100–₹106, Himalaya Nutravedics is valued at approximately 9.04x–12.63x based on the stated pre-IPO and post-IPO EPS figures. The company reported an FY2026 EPS of ₹11.72 on a pre-issue basis and ₹8.39 on a post-issue basis. For FY2026, the company reported ROE of 63.87%, ROCE of 36.41%, RoNW of 45.12% and EBITDA margin of 18.82%.
Objects of the Issue
The ₹26.50 crore IPO is a 100% Fresh Issue of 25.00 lakh equity shares. The company proposes to utilise the net proceeds towards funding working capital requirements, business development and digital marketing activities, and general corporate purposes.
- The company proposes to utilise the IPO proceeds for:
- Funding Working Capital Requirements.
- Business Development and Digital Marketing Activities.
- General Corporate Purposes.
Promoters, Lead Managers & Registrar
Himalaya Nutravedics India Limited is promoted by Rohit Asawa, Divya Asawa, Chanda Asawa and Rama Raju Penmatsas. Nirbhay Capital Services Pvt. Ltd. is the Book Running Lead Manager to the issue and Kfin Technologies Ltd. is the Registrar to the Issue.
Promoters
Lead Managers (BRLM)
Registrar
| Name | Kfin Technologies Ltd. |
|---|---|
| Phone | 040-79615565 |
| himalaya.ipo@kfintech.com | |
| Website | https://ipostatus.kfintech.com/ |
Himalaya Nutravedics IPO Review
Himalaya Nutravedics operates in the Ayurvedic and nutraceutical manufacturing segment, with capabilities covering multiple dosage forms and a business model that combines own-brand marketing with third-party contract manufacturing.
The company has reported significant improvement in its financial performance. Total income increased from ₹14.43 crore in FY2024 to ₹21.00 crore in FY2025 and ₹43.12 crore in FY2026. Profit after tax increased from ₹0.43 crore in FY2024 to ₹2.23 crore in FY2025 and ₹7.39 crore in FY2026.
The company has also reported an EBITDA of ₹8.10 crore and an EBITDA margin of 18.82% for FY2026. Its FY2026 ROE was 63.87%, ROCE was 36.41%, RoNW was 45.12% and debt-to-equity stood at 0.31.
The IPO proceeds are proposed to support working capital as well as business development and digital marketing activities. These uses are aligned with the company's expansion plans and operating requirements.
At the upper IPO price of ₹106, the post-issue market capitalization is approximately ₹93.35 crore. The post-issue P/E based on the stated post-issue EPS of ₹8.39 is approximately 12.63x.
Investors should also consider the company's relatively short operating history since incorporation in 2022, the competitive nature of the Ayurvedic and nutraceutical industry, regulatory requirements and the risks disclosed in the offer documents before making an investment decision.
How to Apply
Himalaya Nutravedics IPO applications can be made through ASBA or UPI during the subscription period from September 22, 2026 to September 24, 2026. The minimum application is 2 lots of 1,200 shares, or 2,400 shares, requiring ₹2,54,400 at the upper price band of ₹106.
Through UPI
- Log in to your stockbroker app or website.
- Go to the IPO section.
- Select Himalaya Nutravedics IPO.
- Enter the number of lots you want to apply for.
- Select the bid price. Retail investors can generally choose Cut-off when available.
- Enter your valid UPI ID.
- Submit the IPO application.
- Open your UPI app when the mandate request arrives.
- Approve the mandate using your UPI PIN.
- The application amount will be blocked in your bank account. If shares are allotted, the required amount will be debited; otherwise, the blocked amount will be released.
Prospectus & Documents
Investors can refer to the company's DRHP, RHP and Prospectus for detailed information about the business, financial performance, risk factors, IPO structure and utilisation of the issue proceeds. The company has an IPO section on its official website containing links for the Draft Red Herring Prospectus, Draft Abridged Prospectus, Addendum, Red Herring Prospectus and Prospectus.
Last updated Sep 16, 2026.